LY4256984 / Eli Lilly - LARVOL DELTA

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

Eli Lilly and Company has launched a long term extension study called “A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis" (The Globe and Mail) - "The extension is planned to run for about 96 weeks, building on the prior J6I-MC-OWAA study under the broader OLMP master protocol. The study was first submitted on April 30, 2026, and the record was last updated on May 11, 2026, while recruitment is still listed as not yet started."

New P1 trial • Amyotrophic Lateral Sclerosis

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

J6I-MC-OWAA: Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis (clinicaltrialsregister.eu) - P1 | N=30 | Recruiting | Sponsor: Eli Lilly & Co.

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

Design of the multiple ascending dose (MAD) trial of UNC13A splice modulating ASO LY4256984 in patients with sporadic amyotrophic lateral sclerosis (ALS) (ALS-MND 2025) - "Results to date: The trial initiated enrollment in 2025 and plans to be conducted in ≥10 sites. We will test the safety and tolerability of intrathecally administered UNC13A splice modulating ASO LY4256984 in patients with sporadic ALS."

Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • TARDBP

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders